Non-valvular atrial fibrillation (NVAF) is a common heart rhythm disorder characterized by irregular and often rapid heartbeats. Unlike valvular atrial fibrillation, which is associated with heart valve issues, NVAF occurs in the absence of significant valve abnormalities. NVAF poses an increased risk of blood clots forming in the atria, which can potentially lead to stroke. Managing NVAF typically involves anticoagulant medications to prevent blood clot formation and control heart rate. Additionally, healthcare providers may explore rhythm control strategies to restore a normal heart rhythm. As NVAF is often a chronic condition, a comprehensive approach that considers individual patient factors is crucial for effective treatment and reducing the risk of associated complications. Regular monitoring and collaboration between patients and healthcare professionals are key components of managing non-valvular atrial fibrillation.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India